ODM derived from

  1. 11/12/2013 11/12/2013 - Martin Dugas
  2. 14/04/2014 14/04/2014 - Julian Varghese
  3. 13/04/2021 13/04/2021 - Dr. rer. medic Philipp Neuhaus
  4. 20/09/2021 20/09/2021 -
Téléchargé le:

20 septembre 2021

Pour une demande vous connecter.
Licence :
Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility DRKS00003823 NCT00478777 Relapsed or Refractory Multiple Myeloma


  1. StudyEvent: Eligibility
    1. Eligibility
Alter mindestens 18 Jahre
Must understand and voluntarily sign an informed consent form.
Must be >=18 years of age at the time of signing the informed consent form.
Must be able to adhere to the study visit schedule and other protocol requirements.
Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment.
Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first dose of study drug with the exception of radiation therapy initiated prior to or at baseline (Day 1).
Measurable levels of myeloma paraprotein in serum (>0.5 g/dL) or urine (>0.2 g excreted in a 24-hour collection sample).
ECOG Status <= 2
The presence of any of the following will exclude a subject from study enrollment:
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Pregnant or lactating females.
Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
Any of the following laboratory abnormalities:
Absolute Neutrophil Count
Platelet count <75,000/mm^3 (75 x 109/L) for subjects in whom <50% of the bone marrow nucleated cells are plasma cells.
Platelet count <30,000/mm^3 (30x10^9/L) for subjects in whom >=50% of bone marrow nucleated cells are plasma cells.
Kreatinin im Serum
Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN)
Serum Total Bilirubin Measurement
Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for >=1 year.
Prior history of stroke and/or thromboembolic event
Known hypersensitivity to thalidomide or dexamethasone.
Prior history of uncontrollable side effects to dexamethasone therapy.
The development of a desquamating rash while taking thalidomide.
Neuropathy >= Grade 2.

Similar models

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial